Skip to main content

Dr. Wendy C. Moore, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
35
In the NPI registry since
2005
Medicare patients seen, 2024
83

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1991Medical school: University of Maryland School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    NC license 2000 00556
  • Critical Care Medicine (Internal Medicine) Physician
    NC license 2000 00556

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
83
Services billed
10,617
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, mepolizumab, 1 mg3,80011
Injection of drug or substance under skin or into muscle7125
Established patient office or other outpatient visit, 30-39 minutes5542
Established patient office or other outpatient visit, 40-54 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 3 payments worth $283 in total to this clinician.

By type
Travel and Lodging$186
Food and Beverage$97.38

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 21, 2025AstraZeneca Pharmaceuticals LP
Feb 21, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$115
Feb 21, 2025AstraZeneca Pharmaceuticals LP
Feb 21, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$70.67

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 5 companies. The companies reported $213,370 in research payments for these studies, mostly to the institutions running them.

  • A randomized, double-blind, parallel group, multi-center study to eval
    GlaxoSmithKline, LLC.
  • A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
    AstraZeneca Pharmaceuticals LP
  • A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
    Teva Pharmaceuticals USA, Inc.
  • Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
    AstraZeneca Pharmaceuticals LP
  • A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
    Amgen Inc.
  • A prospective, real-world, interventional study to evaluate the effect
    GlaxoSmithKline, LLC.
  • A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose…
    AstraZeneca Pharmaceuticals LP
  • The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
    AstraZeneca Pharmaceuticals LP
  • A 52-week, randomised, double-blind, double-dummy, parallel group, mul
    GlaxoSmithKline, LLC.
  • A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
    GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Winston Salem

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 15, 2008), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1235112376. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.